



May 15, 2025

Ref:- GH/2025-26/EXCH/14

The General Manager  
Dept. of Corporate Services  
BSE Limited,  
P J Towers, Dalal Street,  
Mumbai - 400 001

The Manager  
Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex,  
Bandra (E), Mumbai - 400 051

**Scrip Code: 543654**

**Symbol: MEDANTA**

**Sub:** Press Release

Dear Sir(s),

Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Press Release, for the fourth quarter and financial year ended March 31, 2025 Results.

Kindly take the above on record.


Thanking you,

Yours faithfully

**For Global Health Limited**

**Rahul Ranjan**  
**Company Secretary & Compliance Officer**  
**M. No. A17035**

**Encl: a/a**



**Medanta reported a strong quarterly performance and announced its first ever dividend of 25% (INR 0.50 per share)**

**Total income of INR 9,542 million; up by 14% in Q4 FY25. EBITDA of INR 2,476 million, up by 20% y-o-y; with strong EBITDA margins of 26.0%**

**Both matured and developing hospitals reported y-o-y revenue growth of 5% and 24% respectively in Q4 FY25**

**Strong balance sheet with net cash position of INR 8,123 million as at 31<sup>st</sup> March, 2025**

**Gurugram, May 15<sup>th</sup>, 2025:** Global Health Limited (NSE: [Medanta](#), BSE: [543654](#)), one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India, today announced its audited consolidated financial results for the quarter and full year ending 31<sup>st</sup> March, 2025.

**Consolidated Highlights of the Year Ended 31st March, 2025 (FY2025)**

- Consolidated Total Income of INR 37,714 million, grew by 12.6% y-o-y. The growth was primarily driven by increase in patient volumes
- EBITDA was INR 9,562 million, growth of 9.4% y-o-y. EBITDA margins stood at 25.4% compared to 26.1% in FY24
- Profit After Tax was INR 4,813 million, with PAT margins of 12.8%
- Profit After Tax was impacted due to non-recurring exceptional expense item of INR 499 million arising due to merger of MHPL (Lucknow entity) with GHL. Adjusted PAT was INR 5,186 million with margins of 13.8% and growth of 8.5% y-o-y
- The board of directors have recommended a final dividend of 25% on the face value of INR 2 per share i.e. INR 0.50 per share
- During the year, 219 new beds were added, growth of 7.8% y-o-y, comprising of 49 beds at Gurugram, 58 at Lucknow and 112 beds at Patna hospital
- Occupied bed days increased by 10.0%, representing an occupancy of 62.1% on increased bed capacity
- ARPOB grew marginally by 1.3% y-o-y to INR 62,722 in FY2025
- In-patients count increased by 11.7% and Out-patients count increased by 9.5% y-o-y
- Matured hospitals revenue was INR 26,118 million, growth of 9.6% on y-o-y basis. EBITDA was INR 6,481 million, growth of 8.0% y-o-y
- Developing hospitals revenue was INR 10,940 million, growth of 10.0% on y-o-y basis. EBITDA was INR 3,290 million, growth of 2.6% y-o-y
- During the period, International Patients Revenue increased by 7.8% y-o-y to INR 2,086 million, driven by increased international patient volume
- OPD Pharmacy (Hospital & Retail) continues to register strong growth. Revenue increased by 26% y-o-y to INR 1,400 million in FY25

**Consolidated Highlights of the Quarter Ended 31st March, 2025 (Q4 FY2025)**

- Consolidated Total Income of INR 9,542 million, grew by 14.1% y-o-y, primarily led by patient volume growth
- EBITDA was INR 2,476 million, growth of 19.8% y-o-y. EBITDA margins improved from 24.7% in Q4 FY24 to 26.0% in Q4 FY25
- Profit After Tax was INR 1,014 million with PAT margins of 10.6%
- In Q4 FY25 Profit After Tax is impacted due to non-recurring exceptional expense item of INR 499 million arising due to merger of MHPL with GHL. Adjusted PAT was INR 1,387 million with margins of 14.5% and growth of 8.9% y-o-y
- Occupied bed days increased by 12.3% y-o-y, representing an occupancy of 61.3% on increased bed capacity
- ARPOB grew marginally by 0.9% y-o-y to 63,629 in Q4 FY25. In-patients count increased by 15.2% and Out-patients count increased by 12.9% y-o-y
- Matured hospitals revenue was INR 6,389 million, growth of 4.5% on y-o-y basis. EBITDA was INR 1,535 million, de-growth of 0.8% y-o-y
- Developing hospitals revenue was INR 2,814 million, growth of 24.2% on y-o-y basis. EBITDA was INR 871 million, growth of 40.0% y-o-y
- During the quarter, International Patients Revenue increased by 17% y-o-y to INR 557 million, driven by increased international patient volume
- OPD Pharmacy (Hospital & Retail) business continues to register strong growth. Revenue increased by 27.3% y-o-y to INR 340 million in Q4 FY25

**Commenting on FY2025 results, Mr. Pankaj Sahni, Group CEO and Director said:**

“FY2025 was a landmark year for us as we celebrated 15 years of our flagship facility in Gurugram – the foundation of our journey in delivering world-class, patient-centric care. We are deeply honoured that Medanta Gurugram, also known as “The Medicity,” has been ranked India’s Best Private Hospital by Newsweek for the sixth consecutive year. This recognition is a testament to our unwavering focus on clinical excellence and innovation.

Throughout the year, we remained steadfast in our commitment to providing the highest quality of patient care while continuing to invest in strengthening our clinical and technological capabilities across the Group.

We are excited about our upcoming 550-bed facility in Noida, which is on track to commence operations in Q2 FY2026. This is part of a broader plan to add 1,000 beds over the next two years, enhancing our capacity to serve growing patient needs.

In addition, we announced three significant greenfield projects in the high-growth markets of Mumbai, Pitampura, and Guwahati. These projects, expected to be operational in the next 3–4 years, will not only expand our footprint but also meaningfully diversify our presence across the country.”

### **Key Developments – FY2025**

- Total 219 new beds were added, growth of 7.8% y-o-y, comprising of 49 beds at Gurugram, 58 at Lucknow and 112 beds at Patna hospital
- Inaugurated dedicated mother and child floor with 49 beds, including 25+ dedicated neonatal beds in Medanta-Gurugram
- Launched Medanta Clinics at Golf Course Road in Gurugram and at Ranchi
- On-boarded 100+ doctors including 45+ associate consultant and above doctors, to further strengthen clinical capabilities
- Magnetom Vida MRI System with Paradigm Generator Da Vinci Xi robotic system operationalized at Gurugram in Q2 FY25
- Introduced Surgical Robot Da Vinci Xi at Lucknow and launched Uttar Pradesh 1st 5G Enabled Ambulance in Lucknow

### **Building Strong Pipeline for Future Expansion:**

- **Noida:** Development of a greenfield hospital is in full swing and is expected to be operational by Q2 FY2026
- **Mumbai:** Acquired 9,288 sqm of prime land in Oshiwara to develop a 500+ bed super-specialty hospital
- **Pitampura, Delhi:** Signed an Operations and Management agreement with Society to jointly build and operate and manage a ~750 bed super speciality hospital at Pitampura, New Delhi
- **Ranchi:** Signed O&M agreement to operate a 110-bed hospital with advanced OTs and critical care facilities, expected to be operational in Q1 FY2026
- **Guwahati:** Board has approved project to acquire land and build a 400 bedded super-specialty destination care hospital in Guwahati to serve the entire region of Northeast India

### **Clinical Achievement – FY2025**

- Medanta Lucknow successfully performed the Group's first CAR-T cell therapy, marking a significant milestone in advanced cancer care. Following this, Medanta Gurugram also conducted CAR-T cell therapy—an innovative treatment that leverages the patient's own immune system to combat cancer
- Medanta Lucknow becoming known as a centre of excellence for robotic surgeries in Uttar Pradesh. 100+ robotic surgeries in first 6 months
- Medanta Lucknow crossed the milestone of 250+ kidney transplants since inception. Establishing itself as a leading centre for renal transplantation in the region

- Medanta Gurugram successfully addresses a complex case of peripheral arterial disease with Stealth Orbital 360 Atherectomy – setting a new standard of care, with a focus on re-intervention if needed in a 'leave no metal behind' approach
- Medanta Patna saves infant through early detection of Trichohepatoenteric Syndrome - one of world's rarest disorders
- Medanta Gurugram patents Brachytherapy device MAOLO for advanced Cervical Cancer treatment
- Medanta Gurugram doctors uses minimally invasive unique approach to treat rare heart condition Idiopathi Chylopericardium
- Medanta Gurugram successfully performed a complex 14-hour surgery on a 2-year-old boy to remove a rare facial tumour (Myofibroblastoma)

### **Financial Highlights: Q4 and FY2025**

INR million	Year End			Quarter			
	FY24	FY25	Y-o-Y Growth %	Q4 FY24	Q3 FY25	Q4 FY25	Y-o-Y Growth %
<b>Revenue from operations</b>	<b>32,751</b>	<b>36,923</b>	<b>12.7%</b>	<b>8,086</b>	<b>9,434</b>	<b>9,312</b>	<b>15.2%</b>
Other income	747	791	5.9%	274	160	229	(16.4)%
<b>Total income</b>	<b>33,498</b>	<b>37,714</b>	<b>12.6%</b>	<b>8,361</b>	<b>9,595</b>	<b>9,542</b>	<b>14.1%</b>
Cost of materials consumed	7,594	8,797	15.8%	1,937	2,292	2,136	10.3%
Employee benefits expense	11,619	13,219	13.8%	2,959	3,300	3,356	13.4%
Other expenses	5,548	6,137	10.6%	1,397	1,465	1,573	12.6%
<b>EBITDA</b>	<b>8,737</b>	<b>9,562</b>	<b>9.4%</b>	<b>2,068</b>	<b>2,538</b>	<b>2,476</b>	<b>19.8%</b>
<b>EBITDA Margins %</b>	<b>26.1%</b>	<b>25.4%</b>	<b>(73) bps</b>	<b>24.7%</b>	<b>26.5%</b>	<b>26.0%</b>	<b>122 bps</b>
Finance costs	739	653	(11.7)%	182	163	150	(17.5)%
Depreciation and amortisation expense	1,727	1,937	12.2%	455	484	493	8.4%
Exceptional item	0	499	na	0	0	499	na
<b>Profit before tax</b>	<b>6,271</b>	<b>6,473</b>	<b>3.2%</b>	<b>1,431</b>	<b>1,891</b>	<b>1,334</b>	<b>(6.7)%</b>
Tax expenses	1,490	1,659	11.3%	157	462	321	103.7%
<b>Profit after tax</b>	<b>4,781</b>	<b>4,813</b>	<b>0.7%</b>	<b>1,273</b>	<b>1,429</b>	<b>1,014</b>	<b>(20.4)%</b>

#### **Note:**

1. In Q4 FY25 and FY25, PBT and PAT is impacted due to non-recurring exceptional expense item of INR 499 million arising due to merger of MHPL with GHL. PAT Growth in Q4 FY25 and FY2025 adjusted for one-time expense was 8.9% y-o-y and 8.5% y-o-y
2. Previous period figures have been regrouped/reclassified to conform to the current period's classification

\*\*\*\*\*

**About Global Health Limited (Medanta)**

Founded by Dr. Naresh Trehan, a world-renowned cardiovascular and cardiothoracic surgeon who has been awarded the prestigious Padma Bhushan and the Padma Shri, the third- and fourth-highest civilian awards in India, and the Dr. B.C. Roy Award in recognition of his distinguished contribution to medicine.

Global Health Limited (the "Company") is one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India, with key specialties cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopedics, liver transplant, and kidney and urology, according to the report titled "An assessment of the healthcare delivery market in India, September 2022" by CRISIL Limited.

Under the "Medanta" brand, the Company has a network of five hospitals currently in operation (Gurgaon, Indore, Ranchi, Lucknow, and Patna). Spanning an area of 4.7 million sq. ft., its operational hospitals have 3,042 installed beds as on March 31, 2025. It also has one hospital under-construction in Noida. The Company provides healthcare services in over 30 medical specialties and engages over 1,850+ doctors led by highly experienced department heads.

For more information visit [www.medanta.org](http://www.medanta.org) or contact:

Global Health Limited	
<b>Ravi Gothwal</b> <a href="mailto:ravi.gothwal@medanta.org">ravi.gothwal@medanta.org</a>  Tel: 0124 – 4141 414	<b>Bhushan Khandelwal</b> <a href="mailto:bhushan.khandelwal@medanta.org">bhushan.khandelwal@medanta.org</a>  Tel: 0124 – 4141 414

**Safe Harbour Disclaimer**

This press release, apart from historical information, contains some "forward-looking statements" including those describing the Company's strategies, strategic direction, objectives, future prospects, estimates etc. These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by these statements. These factors include, but are not limited to general market conditions, macro-economic, movements in currency exchange and interest rates, the ability to attract and retain high quality human resource, competitive pressures, technological developments, governmental and regulatory trends, legislative developments, and other key factors beyond the control of the Company.

These forward looking statements are based on information currently available to us, and we assume no obligation to revise these statements as circumstances change. The Company may alter, modify or otherwise change in any manner the content of Presentation/Press Release, without obligation to notify any person of such revision or changes.